Lupus :: Over one-third of refractory lupus patients remain stable at long term follow-up
Health is a unity and harmony within the mind, body and spirit which is unique to each person, and is as defined by that person. The level of wellness or health is, in part, determined by the ability to deal with and defend against stress. Health is determined by physiological, psychological, socio-cultural, spiritual, and developmental stage variables.
Over one-third of refractory lupus patients remain stable at long term follow-up

Lupus :: Over one-third of refractory lupus patients remain stable at long term follow-up
Thirty-six percent of patients with refractory systemic lupus erythematosus remain well after undergoing B-cell depletion therapy without needing further standard immunosuppressive agents, according to a study presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
Overactive B-cells are commonly found in patients with SLE and reducing the number of B-cells in the system by BCDT has been suggested as a promising therapy for SLE patients who are unresponsive to other treatments.
In this study, initiated in 2000, patients with refractory SLE were treated with BCDT (based on rituximab) using a combination protocol with cyclophosphamide and steroids. Of the 33 patients who had a minimum of 6 months follow-up duration at the time of analysis (mean duration 37 months, range 6-79), 12 patients remained well. Median duration of B-cell depletion was 4 months (range 2-15), with 2 patients remaining depleted at time of analysis (73 and 8 months respectively). B-cell depletion was beneficial clinically, with a decrease of median global BILAG scores (clinical activity index ? see Editors note) from 13 to 5 when measured between 5 and 8 months p
(
Lupus :: Over one-third of refractory lupus patients remain stable at long term follow-up published at
SpiritIndia on Thursday, June 14, 2007)